Latham & Watkins Advises Ascendis Pharma A/S in Public Offering of ADSs

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new treatments that make a meaningful difference in patients’ lives, has announced the pricing of its underwritten public offering of 2,500,000 American Depositary Shares (ADSs), each of which represents one ordinary share of Ascendis, at a price to the public of US$160 per ADS. All of the ADSs are being offered by Ascendis. The offering is expected to close on or about September 7, 2021 subject to customary closing conditions. In addition, Ascendis has granted the underwriters a 30-day option to purchase up to an additional 375,000 ADSs at the public offering price, less the underwriting commissions.

Latham & Watkins LLP represented Ascendis Pharma A/S in the transaction with a corporate deal team led by Bay Area partners Mark Roeder and John Williams, with associates Zuzanna Gruca, Chris Lim, and Ryan Wong. Advice was also provided on intellectual property matters by Bay Area partner Judith Hasko, with associate Katie Mladinich; on regulatory matters by Washington, D.C. partner Ben Haas, Brussels partner Héctor Armengod and Bay Area counsel Betty Pang; on privacy and data security matters by Bay Area counsel Heather Deixler; and on tax matters by New York partner Elena Romanova, with associate Michael Yu.